The Jackson Research Group is focused on furthering our understanding of the pathogenesis of childhood asthma. Dr. Jackson has led studies aimed at identifying mechanisms of disease inception and exacerbation, and clinical trials to identify optimal treatment of asthma. The ultimate goal of his research is to develop and test effective approaches for the modification and prevention of asthma in children.
Dr. Jackson is the PI of the NIAID-funded Inner City Asthma Consortium (ICAC) which is focused on improving our understanding of mechanisms underlying the greater incidence and severity of asthma and allergic disease in urban children, particularly those living in poverty. The consortium aims to identify novel therapies to address the significant disease burden in this high-risk population.
Dr. Jackson is the PI of the Childhood Origins of ASThma (COAST) birth cohort study initiated in 1998. COAST has focused on host-environment interactions in the development of childhood asthma and has identified important relationships among type 2 inflammation, viruses and other microbes in the inception of asthma. COAST is currently part of the Childhood Respiratory and Environmental Workgroup (CREW) birth cohort consortium funded by NIH.
Dr. Jackson is also the UW-Madison site PI for the multi-center Oral Bacterial Extracts for the Prevention of Wheezing/Asthma (ORBEX) study funded by NHLBI, UW-Madison site PI for the multi-center Preventing Asthma in High-Risk Kids (PARK) study funded by NIAID, and a co-investigator and pediatric committee co-chair for the Precision Interventions for Severe and Exacerbation Prone Asthma (PrecISE) network funded by NHLBI.
Research News

Get to know the new chief of the Division of Allergy, Immunology, and Rheumatology: Q&A with Daniel Jackson
On September 1, the University of Wisconsin School of Medicine and Public Health Department of Pediatrics saw one of its most accomplished faculty members, and one of the world’s leading childhood-asthma researchers, take the leadership …
September 4, 2026
Daniel Jackson receives WARF Named Professorship
Daniel Jackson, MD, professor, Division of Allergy, Immunology, and Rheumatology, was selected for the prestigious WARF Named Professorship award and has chosen the name “Robert F. Lemanske, Jr. Professor of Pediatrics” for the chair. The award, which …
August 19, 2026
Study discovers new complexity in inflammatory pathways causing asthma attacks in children
Mepolizumab is a biologic asthma therapy that targets a type of inflammation called type 2 (T2). It was approved by the FDA in 2015 and has been shown to be effective in studies of adults …
August 6, 2025
Courtney Gaberino wins first place at 20th Annual Respiratory Disease Young Investigators’ Forum
Courtney Gaberino, MD, clinical instructor in the Division of Allergy, Immunology, and Rheumatology and a member of the Jackson Research Group, recently attended the 20th Annual Respiratory Disease Young Investigators’ Forum in Denver, Colorado, where she received first place for …
January 21, 2025
How old ‘redlining’ policies still affect childhood asthma risk
This article was originally published by Cincinnati Children’s and shared nationally through PR Newswire on September 24, 2024. Read the original article. An old government policy that determined who was eligible to receive government-supported home …
October 9, 2024- More News...

Professor
djj@medicine.wisc.edu